Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren's syndrome.
Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren's syndrome.
复制标题
对市售口腔保湿剂缓解放射后头颈癌患者和干燥综合征患者口干症状和体征的临床评估。
DOI：
--
复制
发表时间：
2000
期刊：
影响因子：
--
通讯作者：
J. Bereuter
中科院分区：
文献类型：
--
作者：
N. Rhodus;J. Bereuter
放射治疗头颈癌的主要并发症是唾液腺功能障碍和口干。本临床研究的目的是评估市售口服保湿剂（optimist）对放疗后头颈癌患者（XRT）和Sjögren综合征（SS）患者的唾液流率、口干症状、口腔pH值、口腔微生物群和吞咽的影响。xrt后受试者和SS患者（n = 24，平均年龄= 54.1）在进入研究前2周停止使用任何唾液替代品或保湿剂。使用标准唾液测定技术收集基线完整未受刺激的唾液5分钟。使用Orion diagnostics， Inc.的试剂盒进行白色念珠菌和乳酸杆菌培养，使用Markson（型号00663）pH计对唾液样本进行pH分析。通过显像透视技术对吞咽进行临床评估。对口干症的症状进行了几项主观评估。指导受试者使用日记，并在两周内随意使用所提供的文章。2周后，结果显示口干症的体征和症状在主观和客观方面均有显著改善。全非刺激唾液流量从（平均+/- SEM） 0.1150 +/- 0.02提高到0.2373 +/- 0.09 mL/min。唾液pH值没有变化。58%的受试者的总体主观口干性改善得到改善。43%的受试者中念珠菌定植减少。乳酸菌定植量没有变化。75%的受试者客观地改善了吞咽。这些结果表明，在放疗后头颈癌患者和SS患者中，使用optimist可显著改善唾液分泌不足和口干症状。
A major complication of irradiation therapy for head and neck cancer is salivary gland dysfunction and xerostomia. The purpose of this clinical investigation was to evaluate the effects of a commercially available oral moisturizer (Optimoist) on salivary flow rate, symptoms of xerostomia, oral pH, oral microflora, and swallowing in postirradiation head and neck cancer patients (XRT) and patients with Sjögren's syndrome (SS). Subjects who were post-XRT and subjects with SS (n = 24; mean age = 54.1) discontinued their use of any salivary substitute or moisturizer for 2 weeks prior to entering the study. Baseline whole unstimulated saliva was collected for 5 minutes using a standard sialometric technique. Candida albicans and Lactobacillus cultures were performed using kits from Orion Diagnostica, Inc., and a pH analysis was performed on the salivary sample using a Markson (model 00663) pH meter. Swallowing was assessed by clinical measures by videofluoroscopic techniques. Several subjective assessments were performed to evaluate symptoms of xerostomia. Subjects were instructed in the use of a daily diary and to use only the provided article ad libitum for a period of 2 weeks. After the 2-week period, the results indicated significant subjective and objective improvements in signs and symptoms of xerostomia. Whole unstimulated salivary flow rate improved from (mean +/- SEM) 0.1150 +/- 0.02 to 0.2373 +/- 0.09 mL/min. Salivary pH did not change. Global subjective improvement in xerostomia improved in 58% of the subjects. Candida colonization decreased in 43% of the subjects. There was no change in Lactobacilli colonization. Swallowing objectively improved in 75% of subjects. These results indicate significant improvement in both signs of hyposalivation and symptoms of xerostomia with the use of Optimoist in postirradiation head and neck cancer patients and patients with SS.